Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2017-08-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | https://www.actamedindones.org/index.php/ijim/article/view/327 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839619474351718400 |
|---|---|
| author | Arvin Pramudita Cleopas M Rumende Ardi Findyartini |
| author_facet | Arvin Pramudita Cleopas M Rumende Ardi Findyartini |
| author_sort | Arvin Pramudita |
| collection | DOAJ |
| description | Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with lower cure rates with the anti-TB therapy and higher risk of developing drug resistance. Some risk factors for this recurrence are smoking, poor treatment adherence, low economic status, and weak immune status. This study is aimed to identify whether the use of fixed-dose combination (FDC) anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation. Methods: the search was conducted on MEDLINE, ProQuest, EBSCO, ScienceDirect, and Cochrane according to clinical question. The studies were selected based on inclusion and exclusion criteria and led to five useful articles. The selected studies were critically appraised for their validity, importance, and applicability. Results: five cohort studies were found with comparable validity. Only 1 study has accurate relative risk (RR) with 3.97 (1.14 – 13.80) and number needed to harm of 18. Other four studies fulfilled the applicability criteria for our case. Conclusion: the use of FDC anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation. |
| format | Article |
| id | doaj-art-d8ef9f23b51b40bb8004095a28daa6f2 |
| institution | Matheson Library |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2017-08-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-d8ef9f23b51b40bb8004095a28daa6f22025-07-23T07:02:28ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322017-08-01492205Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case reportArvin Pramudita0Cleopas M Rumende1Ardi Findyartini2Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaDivision of Pulmonology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, IndonesiaDepartment of Medical Education, Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaBackground: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with lower cure rates with the anti-TB therapy and higher risk of developing drug resistance. Some risk factors for this recurrence are smoking, poor treatment adherence, low economic status, and weak immune status. This study is aimed to identify whether the use of fixed-dose combination (FDC) anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation. Methods: the search was conducted on MEDLINE, ProQuest, EBSCO, ScienceDirect, and Cochrane according to clinical question. The studies were selected based on inclusion and exclusion criteria and led to five useful articles. The selected studies were critically appraised for their validity, importance, and applicability. Results: five cohort studies were found with comparable validity. Only 1 study has accurate relative risk (RR) with 3.97 (1.14 – 13.80) and number needed to harm of 18. Other four studies fulfilled the applicability criteria for our case. Conclusion: the use of FDC anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation.https://www.actamedindones.org/index.php/ijim/article/view/327tuberculosisfixed-dose combinationrecurrent |
| spellingShingle | Arvin Pramudita Cleopas M Rumende Ardi Findyartini Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report Acta Medica Indonesiana tuberculosis fixed-dose combination recurrent |
| title | Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report |
| title_full | Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report |
| title_fullStr | Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report |
| title_full_unstemmed | Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report |
| title_short | Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report |
| title_sort | fixed dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence an evidence based case report |
| topic | tuberculosis fixed-dose combination recurrent |
| url | https://www.actamedindones.org/index.php/ijim/article/view/327 |
| work_keys_str_mv | AT arvinpramudita fixeddosecombinationantituberculosistherapyasariskfactorfortuberculosisrecurrenceanevidencebasedcasereport AT cleopasmrumende fixeddosecombinationantituberculosistherapyasariskfactorfortuberculosisrecurrenceanevidencebasedcasereport AT ardifindyartini fixeddosecombinationantituberculosistherapyasariskfactorfortuberculosisrecurrenceanevidencebasedcasereport |